CYCLOPHOSPHAMIDE FOR INJECTION USP 1000 MG — DIN 02547686
CYCLOPHOSPHAMIDE : 1000 MG · STERIMAX INC · Injection · wholesale supply in Canada
Health Canada status: MARKETED
What is CYCLOPHOSPHAMIDE FOR INJECTION USP?
CYCLOPHOSPHAMIDE FOR INJECTION USP 1000 MG contains CYCLOPHOSPHAMIDE : 1000 MG. It is listed in the Health Canada Drug Product Database under DIN 02547686, held by STERIMAX INC, supplied as Injection for Intravenous administration. Health Canada currently lists it as marketed, status dated 27-Sep-2024. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is CYCLOPHOSPHAMIDE FOR INJECTION USP used for?
Malignant lymphomas, multiple myelomas, leukemias (CLL, CML, AML, ALL), mycosis fungoides, neuroblastoma, adenocarcinoma of the breast, retinoblastoma, and lung neoplasms.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Cyclophosphamide cost around the world?
Cyclophosphamide is listed on 6 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Morocco publishes a PPV (public price); Saudi Arabia publishes a public. Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Australia | ex-manufacturer | 5 | 9 | AUD███.██ |
| Saudi Arabia | public | 7 | 7 | SAR███.██ |
| Morocco | PPV (public price) | 6 | 6 | MAD███.██ |
| United States | acquisition | 2 | 6 | USD███.██ |
| South Africa | single exit price | 2 | 6 | ZAR███.██ |
| United Kingdom | hospital | 4 | 4 | GBP███.██ |
38 pack listings across 26 brand entries and 6 price bases, refreshed 08 Sep 2026. Ranges span every Cyclophosphamide pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Cyclophosphamide in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
8 holders have a Canadian DIN containing Cyclophosphamide, across 28 DINs, of which 12 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| BAXTER CORPORATION | 6 | 6 | PROCYTOX, PROCYTOX TAB 25MG, PROCYTOX TAB 50MG | Sourceable in Canada |
| MARCAN PHARMACEUTICALS INC | 3 | 2 | CYCLOPHOSPHAMIDE FOR INJECTION USP | Sourceable in Canada |
| STERIMAX INC | 3 | 2 | CYCLOPHOSPHAMIDE FOR INJECTION USP | Sourceable in Canada |
| ANDONE PHARMACEUTICAL INC | 2 | 2 | CYCLOPHOSPHAMIDE FOR INJECTION USP | Sourceable in Canada |
| CARTER-HORNER CORP. | 6 | 0 | PROCYTOX FOR INJECTION 2000MG PWS IV, PROCYTOX PWS 500MG, PROCYTOX TAB 25MG, PROCYTOX TABLETS 50MG, PROCYTOX VIAL 1000MG, +1 more | No marketed DIN |
| BRISTOL-MYERS SQUIBB CANADA | 4 | 0 | CYTOXAN PWS FOR INJ 1000MG/VIAL, CYTOXAN PWS FOR INJ 2000MG/VIAL, CYTOXAN TAB 25MG, CYTOXAN TAB 50MG | No marketed DIN |
| ACCORD HEALTHCARE INC | 3 | 0 | CYCLOPHOSPHAMIDE FOR INJECTION | No marketed DIN |
| DR REDDY'S LABORATORIES LTD | 1 | 0 | CYCLOPHOSPHAMIDE FOR INJECTION | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 1000 MG |
|---|---|
| Dosage form | Injection |
| Route | Intravenous |
| Pack configuration (monograph) | 500 mg, 1000 mg, or 2000 mg per vial. |
| Storage | Store at 15-30°C (implied by USP standard, though specific text page 48 is not fully provided). |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Cyclophosphamide |
|---|---|
| ATC code | L01AA01 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02547686 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2547686 |
| Brand name | CYCLOPHOSPHAMIDE FOR INJECTION USP |
| Generic / active ingredient | CYCLOPHOSPHAMIDE : 1000 MG |
| Market authorization holder | STERIMAX INC |
| Health Canada schedule | Prescription |
| ATC code | L01AA01 |
| ATC anatomical main group | L — Antineoplastic and immunomodulating agents |
| ATC therapeutic subgroup | L01AA |
| Current status | MARKETED |
| Status date | 27-Sep-2024 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Administered intravenously. Dosage must be individualized based on clinical response and hematologic tolerance. Monitor leukocyte and platelet counts regularly.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity; urinary outflow obstructions; severe myelosuppression, renal, or hepatic impairment; active infection (e.g., varicella zoster); severe immunosuppression.
Warnings and precautions
Secondary malignancies; acute cardiac/pulmonary toxicity; severe myelosuppression; urotoxicity (hemorrhagic cystitis); hepatotoxicity (VOLD); anaphylaxis.
Is Cyclophosphamide in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Active — reported by ANDONE PHARMACEUTICAL INC (Tier 3 shortage CYCLOPHOSPHAMIDE FOR INJECTION USP" aria-label="Anticipated Tier 3 shortage CYCLOPHOSPHAMIDE FOR INJECTI), last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
12 of 28 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| CYCLOPHOSPHAMIDE FOR INJECTION USP | 2000 MG | POWDER FOR SOLUTION | ANDONE PHARMACEUTICAL INC | MARKETED | 02546744 |
| CYCLOPHOSPHAMIDE FOR INJECTION USP | 1000 MG | POWDER FOR SOLUTION | ANDONE PHARMACEUTICAL INC | MARKETED | 02546736 |
| CYCLOPHOSPHAMIDE FOR INJECTION USP | 2000 MG | POWDER FOR SOLUTION | STERIMAX INC | MARKETED | 02547694 |
| CYCLOPHOSPHAMIDE FOR INJECTION USP | 2000 MG | POWDER FOR SOLUTION | MARCAN PHARMACEUTICALS INC | MARKETED | 02560224 |
| CYCLOPHOSPHAMIDE FOR INJECTION USP | 1000 MG | POWDER FOR SOLUTION | MARCAN PHARMACEUTICALS INC | MARKETED | 02560216 |
| PROCYTOX | 2000 MG | POWDER FOR SOLUTION | BAXTER CORPORATION | MARKETED | 02241800 |
| PROCYTOX | 500 MG | POWDER FOR SOLUTION | BAXTER CORPORATION | MARKETED | 02241798 |
| PROCYTOX | 200 MG | POWDER FOR SOLUTION | BAXTER CORPORATION | MARKETED | 02241797 |
| PROCYTOX | 1000 MG | POWDER FOR SOLUTION | BAXTER CORPORATION | MARKETED | 02241799 |
| PROCYTOX TAB 25MG | 25 MG | TABLET | BAXTER CORPORATION | MARKETED | 02241795 |
2 · Same class — other molecules in ATC L01AA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Cyclophosphamide | CYCLOPHOSPHAMIDE FOR INJECTION · CYCLOPHOSPHAMIDE FOR INJECTION USP · CYTOXAN PWS FOR INJ 1000MG/VIAL · CYTOXAN PWS FOR INJ 2000MG/VIAL · +10 more | 28 | 12 | Yes |
| Bendamustine | BENDAMUSTINE HYDROCHLORIDE FOR INJECTION · BENVYON · ESAMUZE · NAT-BENDAMUSTINE · +1 more | 18 | 11 | Yes |
| Melphalan | ALKERAN · MELPHALAN FOR INJECTION · TARO-MELPHALAN | 8 | 4 | Yes |
| Ifosfamide | IFEX · IFEX PWS 1GM/VIAL · IFEX PWS 2G/VIAL · IFEX PWS 3GM/VIAL · +1 more | 7 | 2 | Yes |
| Chlormethine | LEDAGA · MUSTARGEN | 2 | 1 | Yes |
| Chlorambucil | LEUKERAN | 1 | 1 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC L01A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| L01AX | Dacarbazine · Temozolomide | 42 | 26 |
| L01AC | Thiotepa | 9 | 6 |
| L01AB | Busulfan · Treosulfan | 10 | 4 |
| L01AD | Carmustine · Lomustine · Streptozocin | 8 | 4 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is CYCLOPHOSPHAMIDE FOR INJECTION USP called?
Also recorded in Canada as: cyclophosphamide 500 MG/ML Injectable Solution [Frindovyx] (US), cyclophosphamide 25 MG Oral Capsule (US), cyclophosphamide 50 MG Oral Capsule (US), cyclophosphamide 500 MG Injection (US), cyclophosphamide 1000 MG Injection (US), cyclophosphamide 2000 MG Injection (US), cyclophosphamide 25 MG Oral Tablet (US), cyclophosphamide 50 MG Oral Tablet (US), cyclophosphamide 200 MG/ML Injectable Solution (US), 5 ML cyclophosphamide 200 MG/ML Injection (US), 2.5 ML cyclophosphamide 200 MG/ML Injection (US), 2 ML cyclophosphamide 500 MG/ML Injection (US), 4 ML cyclophosphamide 500 MG/ML Injection (US), 1 ML cyclophosphamide 500 MG/ML Injection (US), cyclophosphamide 100 MG/ML Injectable Solution (US).
The same molecule, Cyclophosphamide, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Endoxan | Latin | Australia, South Africa |
| Cyclophosphamide (NorthStar, USA) | Latin | Australia |
| Cyclophosphamide (Sagent, USA) | Latin | Australia |
| CYCLOPHOSPHAMIDE-REACH | Latin | Australia |
| Cyclonex | Latin | Australia |
| ENDOXAN SUGAR COATED TABLET | Latin | Saudi Arabia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.